SG Americas Securities LLC Buys New Stake in LeMaitre Vascular, Inc. $LMAT

SG Americas Securities LLC bought a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 12,579 shares of the medical instruments supplier’s stock, valued at approximately $1,101,000.

A number of other large investors have also made changes to their positions in LMAT. First Trust Advisors LP boosted its position in shares of LeMaitre Vascular by 52.7% in the 2nd quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock worth $50,829,000 after purchasing an additional 211,280 shares in the last quarter. Envestnet Asset Management Inc. increased its position in LeMaitre Vascular by 6.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 304,556 shares of the medical instruments supplier’s stock valued at $25,293,000 after buying an additional 19,447 shares in the last quarter. Congress Asset Management Co. raised its stake in LeMaitre Vascular by 4.6% in the second quarter. Congress Asset Management Co. now owns 673,968 shares of the medical instruments supplier’s stock valued at $55,973,000 after buying an additional 29,553 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in LeMaitre Vascular in the second quarter worth about $892,000. Finally, American Century Companies Inc. grew its stake in shares of LeMaitre Vascular by 233.0% during the second quarter. American Century Companies Inc. now owns 34,008 shares of the medical instruments supplier’s stock worth $2,824,000 after acquiring an additional 23,794 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on LMAT shares. Roth Capital reaffirmed a “buy” rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday, November 5th. Cantor Fitzgerald reissued a “neutral” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a research report on Monday, November 10th. Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Barrington Research reaffirmed an “outperform” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.20.

LeMaitre Vascular Stock Up 2.0%

Shares of LMAT opened at $88.27 on Friday. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of 38.05, a PEG ratio of 1.96 and a beta of 0.68. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $105.55. The stock’s 50-day moving average price is $84.65 and its 200-day moving average price is $87.39. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.05. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The company had revenue of $61.05 million during the quarter, compared to analysts’ expectations of $62.18 million. During the same period last year, the business earned $0.49 earnings per share. LeMaitre Vascular’s quarterly revenue was up 11.4% on a year-over-year basis. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. On average, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, December 4th. Investors of record on Thursday, November 20th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is 34.48%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.